Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sintilimab and Bevacizumab vs TACE in Intermediate HCC (BEST)
NCT06090656Phase 2Recruiting
- Sponsor
- Sun Yat-sen University
- Start
- Mar 2023
- Primary completion
- Jul 2025
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of sintilimab, bevacizumab in hepatocellular carcinoma (HCC), sponsored by Sun Yat-sen University. Started Mar 2023; status: recruiting.
02
Drugs
sintilimabbevacizumab
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT06090656.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06090656.